FDA Recall Terminated

Benephit XT Infusion System, Targeted Renal Therapy Infusion System, Catalog/REF 70035, STERILE -- AngioDynamics Inc. 603 Queensbury, NY 12804 USA --- COMMON/USUAL NAME - Continuous flush catheter; CLASSIFICATION NAME: Continuous flush catheter; Device Listing # D069932 Benephit Infusion Systems are intended to facilitate targeted renal therapy, or TRT, the delivery of physician-specific agents to the kidneys via the renal arteries. The Benephit Infusion Systems are indicated for use in patients undergoing medical, interventional, or surgical procedures, where the procedure carries an elevated risk of iatrogenic kidney injury for the patient. The Benephit Infusion Systems are also indicated to facilitate TRT in patients who have demonstrated symptoms of acute kidney injury, and whom arterial catheterization for TRT is feasible.

Recall: Z-0509-2012 · Initiated December 5, 2011

Recall

Recall Number
Z-0509-2012
Event Number
60587
Firm
Angiodynamics Worldwide Headquarters
FEI Number
3008319439
Product Code
KRA
Status
Terminated
Root Cause
Nonconforming Material/Component
Initiated
December 5, 2011
Posted
January 11, 2012
Terminated
January 29, 2016
Address
14 Plaza Drive, Latham, NY, 12110-3421

Description

Benephit XT Infusion System, Targeted Renal Therapy Infusion System, Catalog/REF 70035, STERILE -- AngioDynamics Inc. 603 Queensbury, NY 12804 USA --- COMMON/USUAL NAME - Continuous flush catheter; CLASSIFICATION NAME: Continuous flush catheter; Device Listing # D069932 Benephit Infusion Systems are intended to facilitate targeted renal therapy, or TRT, the delivery of physician-specific agents to the kidneys via the renal arteries. The Benephit Infusion Systems are indicated for use in patients undergoing medical, interventional, or surgical procedures, where the procedure carries an elevated risk of iatrogenic kidney injury for the patient. The Benephit Infusion Systems are also indicated to facilitate TRT in patients who have demonstrated symptoms of acute kidney injury, and whom arterial catheterization for TRT is feasible.

Reason

The Benephit XT Infusion System may contain hairline cracks in the sheath hub.

Action

Angiodynamics Worldwide Headquarters sent a Urgent Medical Device Recall Letter and Response Forms dated December 2, 2011, to all affected customers via Certified Mail on December 5, 2011. The recall is being extended to the medical user level. Customers will be instructed not to use the product and to return it to AngioDynamics, Inc. in Queensbury, NY. A Return Authorization number (RA #) will be assigned to each customer in the recall notification letter and a UPS account will be provided for return freight. A reply form was provided with the recall notification letter to be completed by each consignee. ACTIONS TO BE TAKEN BY CUSTOMER / USER: (1.) Identify and segregate the recalled lots that are in your possession. (2.) Complete the enclosed Benephit XT Infusion System Recall Reply Form and fax it to the attention of the Benephit XT Infusion System Recall Coordinator at 518-798-1360. The form lists the catalog number, lot numbers, and quantity our records indicate your facility has received. It is important that even if you do not have any product remaining in your possession that you fill out the attached form noting zero quantity to be returned and fax the form to ANGIODYNAMICS. (3.) Ship the recalled product to ANGIODYNAMICS. Replacement product will be shipped upon receipt and confirmation of the returned product. Reference Return Authorization Number on the outside of the shipping box and include a copy of the Benephit Infusion System Recall Reply Form with your shipment. (4.) If you have distributed the affected product/lot, please inform your customers of this recall action immediately, and have them return the recalled units to you. --- Certified Mail will verify delivery to each domestic consignee. Non-respondents will be contacted by telephone or via e-mail. --- Corrective Action: Returned product will be quarantined and final disposition has not been determined at this time. A corrective action has been initiated by AngioDynam

Distribution

Nationwide Distribution including the states of New York, Pennsylvania, Virginia, Kentucky, Iowa, Illinois, Missouri, Louisiana, Texas, and Utah.

Quantity

55 units domestically